Podcast appearances and mentions of Ryan Sullivan

This week we are joined by Ryan Sullivan. Ryan is a pro golfer that is working towards the PGA Tour. Check out his instagram below to keep up with him.Check him out at instagram.com/rsully_89The BSG Podcast is brought to you by Moon Golf. They offer golf equipment, apparel, fittings, re-gripping, and anything else you can think of. Go check out Moon Golf and see why their customer service is so highly rated. www.moongolf.com @moongolfshopSubscribe to the Be.Still Golf channel: / bestillgolf Follow along with Be.Still Golf Here: Instagram - / be.stillgolf Facebook - / be.stillgolf

Ryan joins Chris and Ashley as they talk about and reminisce about display (or open) kitchens. Chris' dreams came true when he hired Ryan almost 20 years ago to be the pretty face behind the curtain... errr... in this case, there was no curtain. Feierabend was an open kitchen and we cover all the pros and cons and funny stories along the way.

Today's special episode features three segments.PART 1: A 5 Yrs Ago Wade Keller Pro Wrestling Podcast Mailbag hosted by PWTorch editor Wade Keller covering these topics: A potential Aleister Black & Buddy Murphy tag team, whether Bray Wyatt is the Face of WWE already and whether it's a coincidence wrestlers who lose to him go back to their past, could Samoa Joe lead the charge against Seth Rollins & AOP, should Jim Ross be critical of AEW's ring style on air, should AEW have a developmental system to help wrestlers refine their skills, are AEW tag teams in need of curating and closer following of rules, and more.PART 2: Tony Khan's NEW media Q&A from Tuesday this week previewing ROH Final Battle and answering media questions including the relevance of the Hammerstein Ballroom, the state of the Trios Titles, his respect and love for Dustin Rhodes as a wrestler growing up and working with him now, and more.PART 3: The previously VIP-exclusive "Podcast of Honor" podcast with a 2019 Year-in-Review format. Tyler Sage and Ryan Sullivan discuss these topics: Should Marty Scurll have won the world title at G1? Would ROH be in a better place if that had happened? Matt Taven's run on top is debated. Problems with TV and the lack of storylines is discussed. Would WWE buy ROH? Plus, Tyler's WOH manifesto and a ranking of all nine Star Wars films.Become a supporter of this podcast: https://www.spreaker.com/podcast/wade-keller-pro-wrestling-podcast--3076978/support.

In this episode of the Curious Realm host Christopher Jordan welcomes Rob Ryan Sullivan, author A Trek Within and host of the A Trek Within podcast. We discuss the fascinating world of synchronicities, what they are, how to recognize them, and what they may mean for your life. Could it be that the Universe is shooting up flares to guide you, and you just don't know to see them?! In the second part of the episode, we welcome author and researcher Jason Quitt to talk about the geometric keys and clues that have been left for us to decode by ancient civilizations. What do these angles and alignments mean, and could they lead to a new world of understanding of our true connection to the World and Universe around us? Join the Curious Realm as we delve into the topics of interpreting synchronicities with Rob Ryan Sullivan and sacred alignments with Jason Quitt. Curious Realm is proudly distributed by: Ground Zero Media & Aftermath Media, KGRA, APRTV and the official Curious Realm ROKU App! Curious Realm has teamed up with True Hemp Science, Austin, TX based suppliers of high-quality full spectrum emulsified CBD products and more. Visit TrueHempScience.com TODAY and use code Curious7 to save 7% off your order of $50 or more and get a free 50mg CBD edible! Website live streams powered by Web Work Wireless. For the best in home and business WiFi solutions visit WebWorksWireless.com. Intro music “A Curious Realm” provided by No Disassemble find more great music and content at: NoDisassemble.com.Become a supporter of this podcast: https://www.spreaker.com/podcast/curious-realm--5254986/support.

In this episode of the Curious Realm host Christopher Jordan welcomes Rob Ryan Sullivan, author A Trek Within and host of the A Trek Within podcast. We discuss the fascinating world of synchronicities, what they are, how to recognize them, and what they may mean for your life. Could it be that the Universe is shooting up flares to guide you, and you just don't know to see them?! In the second part of the episode, we welcome author and researcher Jason Quitt to talk about the geometric keys and clues that have been left for us to decode by ancient civilizations. What do these angles and alignments mean, and could they lead to a new world of understanding of our true connection to the World and Universe around us? Join the Curious Realm as we delve into the topics of interpreting synchronicities with Rob Ryan Sullivan and sacred alignments with Jason Quitt. Curious Realm is proudly distributed by: Ground Zero Media & Aftermath Media, KGRA, APRTV and the official Curious Realm ROKU App! Curious Realm has teamed up with True Hemp Science, Austin, TX based suppliers of high-quality full spectrum emulsified CBD products and more. Visit TrueHempScience.com TODAY and use code Curious7 to save 7% off your order of $50 or more and get a free 50mg CBD edible! Website live streams powered by Web Work Wireless. For the best in home and business WiFi solutions visit WebWorksWireless.com. Intro music “A Curious Realm” provided by No Disassemble find more great music and content at: NoDisassemble.com.Become a supporter of this podcast: https://www.spreaker.com/podcast/curious-realm--5254986/support.

We brought some joyful and fluid-tastic vibes to this great episode! The main topic involved us picking our jaws off the floor as records were absolutely annihilated at the JFK 50 Mile, America's oldest ultramarathon. We have some inside info on how David Sinclair set the record, which we think could be Ultra Performance of the Year. Plus we worship the queen, Rachel Drake. Why are we seeing record after record get smashed at every major race? The answer likely lies at the intersection of training, shoes, and most of all--fueling. We also talked about a breakthrough new study from the Boston Marathon. Researchers found that the prevalence of low energy availability indicators was associated with worse performance and health outcomes. Find your strong, and you will find your fast! And this one was full of fun topics! Other topics: David recording through fluid adversity, Megan taking one for the team because she loves the podcast mornings, the "Shoot Your Shot" mini-documentary on the Javelina 100, the frontiers of lubrication, lessons from Ryan Sullivan's incredible long-term progression, Shelby Houlihan returning from her ban, why we want to uplift forgiveness, a question on embracing competition, and Listener Corner. We love you all! HUZZAH! Click "Claim Reward" for $80 at The Feed here: thefeed.com/swap Buy a "SLURP" hat: https://thefeed.com/products/the-feed-some-work-all-play-hat Watch the "Shoot Your Shot" mini-documentary: https://www.youtube.com/watch?v=5pzUKGEmvqk Buy Janji's amazing gear: https://janji.com/ (code "SWAP") For weekly bonus podcasts, articles, and videos (plus hat purchases): patreon.com/swap

Take a trip down memory lane with this #ThrowbackThursday episode of A Shot of Business Central and A Beer! Join Ken and Michael as they revisit an insightful conversation with Business Central Integrations specialist, Ryan Sullivan. Whether you're exploring integration possibilities or looking for expert insights into streamlining your Business Central experience, this episode is packed with value. Tune in as Ryan shares his expertise, tips, and real-world solutions that can help you elevate your ERP game!

Send us a textIn this conversation, Ryan shares his journey from soccer to ultra running, discussing his experiences, favorite races, and the importance of sleep and recovery in training. He reflects on his recent achievements, including a strong performance at Leadville 100, and his upcoming participation in DC Peaks 55K. Ryan emphasizes the joy of running and the thrill of competition, while also acknowledging the challenges of balancing training with life commitments.TakeawaysRunning was initially a punishment in soccer for Ryan.Ryan transitioned to ultra running after college and found a passion for it.The importance of sleep and recovery became clear to Ryan during his training.San Juan Solstice 50-Miler stands out as Ryan's favorite race.Working with a coach helped Ryan improve his performance and stay healthy.Ryan enjoys the 50-mile distance the most.The thrill of competition drives Ryan to continue racing despite challenges.Ryan's experience at Leadville 100 was both challenging and rewarding.The beauty of the DC Peaks course excites Ryan for the upcoming race.Learn more about Trail to 100 here- https://trailto100.com/Learn more about DC Peaks Races here- https://www.dcpeaks50.com/Support the show

In this episode I'm joined by Ryan Sullivan to talk about the essential financial literacy needed for success in the AEC industry. We explore how businesses allocate their funds and listeners will learn about key financial terms such as revenue, expenses, and profit, and we'll discuss crucial project-level considerations like overhead, utilization, and billable rates. We also explore how this financial knowledge can inform marketing strategies, focusing on pre-bid work, the go/no-go process, and the importance of ROI. By the end of the episode, you'll have a clearer understanding of how to allocate a percentage of revenue toward effective marketing efforts. About Ryan: Ryan Sullivan, PE is the founder and lead financial planner of Off the Beaten Path Financial. Starting his career as a mechanical engineer, he built an engineering department from the ground up before starting his financial planning firm. His focus is on helping architects and engineers build, grow, and use their wealth to accomplish their biggest dreams. He believes cash flow is the foundation of a strong financial position and helps his clients make sure their money is aligned with their values by building systems that provide peace of mind, financial clarity, and ultimately better decision making. With a precision-driven approach, Ryan blends engineering rigor with calculated risk-taking, ensuring stability while empowering clients to confidently pursue financial abundance. Links: https://www.linkedin.com/in/ryan-sullivan-pe/ https://www.obpfinancial.com/

As science improves, we're learning more and more about brain health and how to maintain our youth even as we age. Today we're joined by Ryan Sullivan, CFP®, CRPC®, RCC™ of Hartford Funds to share the valuable knowledge he's gained from a partnership with the MIT Age Lab and explore how simple lifestyle changes can significantly impact our brain health and, consequently, our financial future. Ryan is the Vice President and Managing Director of Applied Insights with Hartford Funds. They have a partnership with the MIT Age Lab to better grasp how we make decisions and what motivates us as we age. Understanding these insights and how they tie into our finances can help us improve our long-term outlook.      Here's some of what we discuss in this episode: Some of the factors that keep your brain from aging at the same rate as your body. How can you get a sense of what your brain age is? Our brain creates trash that needs to be removed from our bodies or else it will accumulate with enough sleep. The costs that are associated with cognitive health decline and how we incorporate that into retirement planning. Our diet is connected to our brain health.   Check out ‘The Age-Proof Brain': https://a.co/d/9XV4j46   About our guest: https://www.hartfordfunds.com/practice-management/applied-insights-team/john-diehl-bio.html   Visit us online: https://beyondthemaskpodcast.com/   The 1099 CRNA Institute: https://aana.com/1099 ***Use coupon code BEYOND1999 to get 20% off through November 2024   Get the CE Certificate here: https://beyondthemaskpodcast.com/wp-content/uploads/2020/04/Beyond-the-Mask-CE-Cert-FILLABLE.pdf   Help us grow by leaving a review: https://podcasts.apple.com/us/podcast/beyond-the-mask-innovation-opportunities-for-crnas/id1440309246   Donate to Our Heart Your Hands here: https://www.ourheartsyourhands.org/donate    Support Team Emma Kate: https://grouprev.com/haloswalk2024-shannon-shannon-brekken    

Ryan brings dare we say the best mustache in the game to his first attempt at the 100 mile distance at this years LT100. He has a photogenic AF dog, no Instagram, and lots of stoke going into this years race. Follow Ryan (on Strava) - https://www.strava.com/athletes/3791236 Follow Corinne - https://www.instagram.com/corinne_shalvoyage/ Follow Russell - https://www.strava.com/athletes/10753088?oq=russ

Today's economy is wild! Is inflation holding you back on the financial roadmap you created for yourself, fueled by your engineering career?

Engineer to Financial Planner – Ryan Sullivan– ep 148 Starting his career as a mechanical engineer, Ryan built an engineering department from the ground up. In just five years, he built the department into a formidable team of 11 professionals, generating an annual revenue exceeding $1 million. This journey uncovered Ryan's true passion for finance and investing, which led him to starting his financial planning firm. Number one tip: Put your finances on autopilot. Contact info: Obpfinancial.com Linkedin https://www.engineeringcareeraccelerator.com/engineeringentrepreneur   The Engineering Entrepreneur Podcast is produced by Scott Tarcy, President of CADdesignhelp.com. You can reach me at info@caddesignhelp.com.

Overwhelmed by tax planning, payroll checks, or just managing your salary? In this episode, I chat with Ryan Sullivan, an engineer turned financial advisor and founder of "Off the Beaten Path Financial," who breaks down essential money management tips for architects and engineers in the AEC profession. Ryan explains why financial literacy is crucial for architects, how money provides options and flexibility, and shares key lessons from his journey from engineering to finance. He highlights the ability to zoom in and out when solving problems and the similarities between architecture and finance. Ryan offers practical tips on optimizing time, managing cash flow, and diversifying income by productizing services. He also emphasizes a holistic approach to financial planning, covering business strategy, tax planning, retirement plans, and overall financial wellness. Struggling with your finances? Don't miss this episode and start mastering your financial future!   ABOUT THE GUEST:  Ryan Sullivan is the founder and lead financial planner at “Off the Beaten Path Financial”, a firm that specializes in helping architects and engineers. Ryan began his career as a mechanical engineer, where he built an engineering department from the ground up before transitioning to financial planning. He focuses on helping architects and engineers build and grow their wealth to achieve their biggest dreams.  Ryan believes cash flow is the foundation of a strong financial position and works with his clients to ensure their money aligns with their values. He creates systems that provide peace of mind, financial clarity, and better decision-making.   Listen to the Podcast: Spotify: Architect My Business Apple Podcasts: Architect My Business  Podcast Website: www.architectmybusiness.com   Connect with Us! Instagram: @architectmybusinesspodcast LinkedIn: Architect My Business   Get in Touch: Ask Aya anything: www.speakpipe.com/AskAya  Be a Guest: bit.ly/AMBPodcastGuest  

Ryan Sully, founder of Podcast Principles, joins this episode of The Art of Branding, which focuses on distinctive strategic podcasting in a saturated market. Ryan shares insights on how to differentiate your podcast and align podcast strategy with personal and business goals. They discuss why traditional podcast models often fail and how to create content that stands out. The conversation also hits on the balance between creative integrity and practical business tactics when launching and sustaining a successful podcast. 01:20 The podcast boom and its challenges 03:04 Reverse engineering podcast success 04:48 Differentiating your podcast in a crowded market 07:53 Personalization in podcasting 08:36 Combining strategy with personality 11:01 Launching and promoting your podcast 13:38 Overcoming self-doubt and taking risks 16:15 Tips on staying consistent and authentic 30:58 Bloopers and final tips Reach out to featured guest Ryan Sullivan: LinkedIn | Website | YouTube Follow Beatrice Gutknecht: ⁠LinkedIn⁠ | ⁠YouTube⁠ | ⁠Website⁠ ⁠Join The Badass Mob (newsletter)⁠, where boring goes to die each Friday with actionable tips and behind the scenes. Produced by ⁠Your Podcast Sidekick

Cash flow is the foundation of a strong financial position and Ryan helps architects and engineers build financial systems that provide peace of mind, financial clarity, and ultimately better decision-making. Starting his career as a mechanical engineer, he built an engineering department from the ground up. In just five years, he built the department into a formidable team of 11 professionals, generating an annual revenue exceeding $1 million. This journey uncovered Ryan's true passion for finance and investing, which led him to starting his financial planning firm.

Financial Planning for ArchitectsIn this episode, Mark sits down with Ryan Sullivan, PE, the founder and lead financial planner of Off the Beaten Path Financial. Ryan's unique journey from mechanical engineer to financial planner equips him with a distinct perspective on managing finances in the architecture industry.Ryan shares his insights on the critical importance of understanding how money works and the necessity for architects to educate themselves on personal finance. He emphasizes the need to find trusted advisors who prioritize their clients' best interests. Throughout the discussion, Ryan highlights the significance of creating effective systems to manage cash flow and differentiating between variable and fixed expenses.Listeners will gain valuable advice on planning for the future and building a business that can be either sold or passed on. With a strong belief that cash flow is the cornerstone of financial stability, Ryan helps architects ensure their money aligns with their values, providing peace of mind, financial clarity, and better decision-making.This week at EntreArchitect Podcast, Financial Planning for Architects with Ryan Sullivan.Connect with Ryan online at OBP Financial, subscribe to his newsletter, and find him on Twitter and LinkedIn.Please visit Our Platform SponsorsAs an architect or firm owner, you might find yourself swamped with drawings that take up most of your day, leaving you with little time to manage your business. MGS Global Group can lighten your load by handling all your drafting and rendering needs! Visit MGSGlobalGroup.com and book your free consultation today.ARCAT.com is much more than a product catalog, with CAD, BIM, and specifications created in collaboration with manufacturers. ARCAT.com also offers LEED data, continuing education resources, newsletters, and the Detailed podcast. Visit ARCAT.com to learn more.Visit our Platform Sponsors today and thank them for supporting YOU... The EntreArchitect Community of small firm architects.Mentioned in this episode:ArchITShe BuildsBuild Your BrandContext & Clarity

Ryan Sullivan and Joe Lynch discuss the CRO perspective - growing freighttech sales. Ryan is the CEO and Founder of Ratchet Ventures, a fractional CRO firm specializing in the logistics and freighttech space. Summary: The CRO Perspective: Growing FreightTech Sales In this podcast, Ryan Sullivan, Founder of Ratchet Ventures and an experienced Chief Revenue Officer (CRO), shares his insights on growing sales in the freight tech and logistics industry. He discusses the importance of revenue management, transitioning from founder-led sales to a scalable process, and the three levers to increase sales: larger deals, more opportunities, and higher conversion rates. Ryan emphasizes understanding the ideal customer profile, building genuine relationships, and specializing in a specific niche to improve sales performance. He also addresses the challenges growing companies face in finding the right sales leadership and how fractional CRO services can help. Throughout the podcast, Ryan shares his unconventional journey and expertise in helping companies and individuals navigate the increasingly competitive supply chain technology industry. #FreightTechSales #RevenueGrowthStrategies #LogisticsSalesExpertise About Ryan Sullivan Ryan Sullivan is the CEO & Founder of Ratchet Ventures. With over a decade of experience in supply chain tech, Ryan partners with seed to Series B companies to revamp sales strategies, optimize pipelines, and enhance forecasting. A proven leader with success at Kuebix and Tive, he specializes in transitioning from founder-led sales to scalable processes, achieving 5-10x revenue growth. As a 2x founder, 2x corporate exit, and 3-time founding sales leader, Ryan's expertise includes channel partnerships, sales playbooks, prospecting, and CRM enablement. Passionate about innovation in logistics and transportation, he actively shares industry insights on LinkedIn and is committed to transparency and authenticity in all business interactions. Based in Boston, Ryan drives growth and innovation in the supply chain industry. About Ratchet Ventures Ratchet Ventures, led by CEO & Founder Ryan Sullivan, empowers supply chain technology leaders to scale, secure funding, and drive profitable revenue through comprehensive growth services. With over 15 years of experience, Ryan partners with seed to Series B companies to transition from founder-led sales to scalable processes, achieving significant growth. Ratchet Ventures specializes in Fractional CRO services, strategic growth planning, and go-to-market strategies. As a 2x founder, 2x corporate exit, and 3-time founding sales leader, Ryan's expertise is instrumental in navigating startup complexities and driving innovation in the supply chain sector (Ryan Sullivan ). Key Takeaways: The CRO Perspective: Growing FreightTech Sales Gain insights from a Chief Revenue Officer on growing sales in the freight tech industry. Learn about the importance of building relationships with customers. Understand the growing significance of revenue management in companies. Discover how to transition from founder-led sales to a scalable sales process. Hear about Ryan Sullivan's unconventional journey to becoming a successful tech sales leader. Learn three key levers to grow sales in freight tech and logistics companies. Understand the value of genuine expertise and personal connections in the era of AI-generated content. Timestamps (00:00:01) The CRO Perspective on Freight Tech Sales (00:00:20) Fractional CRO for Early Stage Companies (00:01:35) The Growing Importance of Revenue Management (00:04:00) Scaling Sales Beyond Founder-Led Efforts (00:08:05) Accidental Entrepreneur Discovers Supply Chain Tech (00:14:18) Three Levers to Grow Freight Tech Sales (00:16:03) Selling Larger Deals in Freight Brokerage (00:19:34) The Value of Authentic Expertise (00:22:17) Boost Sales Conversion Through Customer Understanding (00:24:32) Niching Down for Higher Conversions (00:32:34) Focusing on the Ideal Customer Profile (00:39:35) Fractional CRO: Helping Companies Overcome Growth Barriers (00:43:21) Fractional CRO: Driving Strategic Sales Growth (00:47:03) Navigating Sales Leadership Challenges in Growing Companies (00:51:48) Three Ways to Grow Freight Tech Sales (00:52:52) Navigating Supply Chain Technology and Capital Learn More About The CRO Perspective: Growing FreightTech Sales Ryan Sullivan | Linkedin Ratchet Ventures | Linkedin Ratchet Ventures The Logistics of Logistics Podcast If you enjoy the podcast, please leave a positive review, subscribe, and share it with your friends and colleagues. The Logistics of Logistics Podcast: Google, Apple, Castbox, Spotify, Stitcher, PlayerFM, Tunein, Podbean, Owltail, Libsyn, Overcast Check out The Logistics of Logistics on Youtube

Have you been thinking about starting a podcast?Do you have a podcast and wonder how you can generate leads from it?Well wonder no more!On this episode of the IBO podcast, we have Ryan R. Sullivan, Founder of Podcast Principles. Most companies "produce" your podcast. Podcast Principles takes the opposite approach. They help founders and CEOs launch profitable podcasts with strategy, first.Ryan is here to school you on how to start a podcast if you don't have one and how you can use your podcast to generate leads.This is a "can't miss" episode!In this episode, you'll learn:How to start a podcastThe easiest way to start generating leads from your podcastSeveral other things you can do with any podcast format to generate leadsYou can find Ryan at Podcast Principles and on socials:LinkedInRyan's podcast:Apple SpotifyYouTubeIf you liked this episode, please leave us a review on Apple Podcasts!

Wisconsin agriculture continues to diversify.  Stephanie Hoff investigates a hoop house farming operation in Manitowoc County, operated by a retired veteran.  Sullivan Family Farm in Manitowoc is growing peas among other specialty crops to live a healthy lifestyle and give back to the community. Ryan Sullivan and his wife are the first generation on the farm following Ryan's 26-year career with the U.S. Air Force. Ryan found support for his family's farm through the Natural Resources Conservation Service, Farmer Veteran Coalition, Marbleseed, and Grassworks, just to name a few. The next step, he says, is to expand the farm's interaction with the public through agri-tourism. Sullivan Family Farm is enrolled in the Wisconsin Agricultural Tourism Association's Peer-to-Peer Mentorship program. Wisconsin's implementing new testing requirements for anyone exhibiting lactating dairy animals at county fairs or exhibitions.  Dr. Darlene Konkle, WI State Veterinarian explains the reason behind the requirement and what exhibitors should expect on testing turn around and costs.Monarch butterflies have led one FFA member from Wausau to the winner's circle at the 95th WI State FFA Convention.  Aubrey Schlimgen visits with Natalie Moran about her interest in the endangered species and gets specifics on how she raises them for her supervised ag experience. See omnystudio.com/listener for privacy information.

Broadband expansion continues across the state of Wisconsin, but many feel it's happening at a snails pace.  Stephanie Hoff gets the straight story from Garin Mayer, CEO of Vernon Communications Cooperative. He says in the past six years, they've gotten nearly $14 million in grants to bring high-speed internet to roughly 4,000 locations. Wisconsin's Local Food Purchase Assistance program has announced 125 state farmers will get funding to pursue growing locally sourced food to battle hunger.  One of those is Sullivan Farm in Manitowoc.  Ryan Sullivan explains how they grow their local food. With new testing requirements in place for any dairy animals that move over state lines, Wisconsin State Fair CEO/Executive Director, Shari Black, is on alert.  Black tells Pam Jahnke that they're monitoring the situation and leaning on Wisconsin's DATCP for guidance on what to expect and how to handle it. Katie Burgess, broker analyst with EverAg, joins Pam Jahnke to talk about the rapid downfall that dairy product prices and fluid milk saw in the markets Wednesday. She says prices are still good, but they did come off the peak.  Burgess also talks about a shift in the "Top 10" list of dairy states, and how retailers have been helping move cheese and butter by featuring it.See omnystudio.com/listener for privacy information.

We're heading into hoop houses in east central Wisconsin to get acquainted with a farm family that produces, in their words, green magic. We're talking about sugar peas. They are fresh, they are green, they are delicious. Sullivan Family Farm in Manitowoc is growing peas among other specialty crops to live a healthy lifestyle and give back to the community. Ryan Sullivan and his wife are the first generation on the farm following Ryan's 26-year career with the U.S. Air Force. Ryan found support for his family's farm through the Natural Resources Conservation Service, Farmer Veteran Coalition, Marbleseed, and Grassworks, just to name a few. The next step, he says, is to expand the farm's interaction with the public through agri-tourism. Sullivan Family Farm is enrolled in the Wisconsin Agricultural Tourism Association's Peer-to-Peer Mentorship program. This podcast series is brought to you courtesy of Specialty Crop Block Grant 23-10. Learn more about how to engage with Wisconsin's agricultural tourism industry at https://gowiagtourism.com/.See omnystudio.com/listener for privacy information.

Discover the insider secrets to podcast success as Ryan Sullivan, a seasoned podcast strategist, joins Phil Better on the latest episode. From setting attainable goals to leveraging personal strengths, they delve into crafting a winning podcast strategy tailored to individual ambitions. Learn how podcasting can fuel business growth and why an outcome-driven approach is key. Tune in to explore the transformative power of investing in yourself through podcasting and personal development.

A new MP3 sermon from Grace Community Church is now available on SermonAudio with the following details: Title: Fasting Matthew 9 Subtitle: Spiritual Disciplines Speaker: Ryan Sullivan Broadcaster: Grace Community Church Event: Sunday Service Date: 1/23/2016 Length: 69 min.

December 23, 2021 - Ryan Sullivan, Sullivan Family Farm

In this special, (non-IBC related) episode of Wealth Warehouse, Dave and Paul sit down with their very own podcast producer, Ryan Sullivan – to talk briefly about what it takes to keep this podcast up and running each and every week!If you're interested in starting a podcast – this episode is a perfect sneak peek into what you can expect in terms of effort and rewards!Episode Highlights:0:00 - Introduction2:16 - Episode beginning3:12 - Some background on how the podcast started6:01 - What were you doing before the podcast?8:03 - Did you envision yourself becoming a podcaster?10:16 - Teaching what you know about14:05 - “Your prospects are watching somebody”15:15 - The co-host experience21:03 - Making a podcast (with help)25:29 - The beauty of a podcast28:55 - Any tips for new creators?31:05 - Most podcasts… fail32:55 - “Don't quit after the first month”35:02 - “For people looking to start a podcast”37:50 - Constructive feedback40:01 - Being authentic41:03 - Closing thoughtsABOUT YOUR HOSTS:David Befort and Paul Fugere are the hosts of the Wealth Warehouse Podcast. David is the Founder/CEO of Max Performance Financial. He founded the company with the mission of educating people on the truths about money. David's mission is to show you how you can control your own money, earn guarantees, grow it tax-free, and maintain penalty-free access to it to leverage for opportunities that will provide passive income for the rest of your life. Paul, on the other hand, is an Active Duty U.S. Army officer who graduated from Norwich University in 2002 with a B.A. in History and again in 2012 with a MA in Diplomacy and International Terrorism. Paul met his wife Tammy at Norwich. As a family, they enjoy boating, traveling, sports, hunting, automobiles, and are self-proclaimed food people. Catch up with David and Paul, visit the links below! Website: https://infinitebanking.org/agents/Fugere494 https://infinitebanking.org/agents/Befort399 LinkedIn: https://www.linkedin.com/in/david-a-befort-jr-09663972/ https://www.linkedin.com/in/paul-fugere-762021b0/ Email: davidandpaul@theibcguys.com

This is DJ Samer and you're listening to the 122nd episode of the Pangea podcast! This month's guest mix is by Pangea artist Hall North, who's had several successful releases as of late including on our own Pangea label. Check out his ‘Guarana' release wherever fine music is sold, and you can even check out cheeky new remixes by me and Seth Vogt in the package as well. Also, our new Spring Sampler is now out on Beatport and includes some great new tracks by the likes of GuyRo, Ryan Sullivan, AUDIOGLIDER and more. You can learn more about our latest releases and podcasts on our website pangearecordings.com. Just a reminder to always support your favorite local artists, and now on to the mix. Featured Artist: Hall North (UK) Tracklist: John O'Donohue - Music                                                Depeche Mode - Waiting For The Night (Hall North Remix) [CDR]                                                        Hall North - Errant Spirits [MIRABILIS]             Hall North - Errant Spirits (Ranj Kaler Remix) [MIRABILIS]                              Hall North - Ayahuasca [PRO B TECH]                           Hall North - Faith" [UNSIGNED EXCLUSIVE]           Hall North - Guarana (DJ Samer Remix) [PANGEA]             Hall North - Guarana (Seth Vogt Remix) [PANGEA]                                                 Hall North - The Whip [UNSIGNED EXCLUSIVE]            Hall North - Thin Places (Glenn Molloy Remix) [MIRABILIS] Please send all promo music to pangea@pangearecordings.com Thank you to all the labels and artists for their support. Visit http://www.pangearecordings.com as all episodes are archived in different formats on the website! Pangea Podcast Landing Page (https://hypeddit.com/djsamer/pangearecordingspodcastepisodecollection) For more information. please “Like” our Facebook Pages: Facebook.com/officialdjsamer Facebook.com/pangearecordings Forward thinking electronic music mixed up by America's leading progressive DJ Samer. For more than 25 years, Pangea Recordings has been at the forefront of American Dance Music and breaking through artists year after year, with over 300 individual releases to its name.  Our supporters span the globe, and are top DJs and Producers such as Sasha, John Digweed, Danny Tennaglia, Cevin Fisher, Jimmy Van M, Hernan Cattaneo, Nick Warren, Paul Oakenfold, Richie Hawtin, Behrouz, Above & Beyond, Max Graham, Booka Shade, Guy J, Microtrauma, Lonya, Henry Saiz, Issac, Baunder (Soundexile), Silinder, Marcelo Vasami, Tini Tun, Aiden, Denis A, CID Inc., Tilt, Betoko, Dan Mangan, Alex Nemec, Barry Jamieson, D:Fuse, Sonic Union, Luke Porter  and more.  Hosted by label boss Samer, this podcast will feature up and coming releases from his self and Pangea Recordings, up and coming producers, as well as legends and pioneers of deep and intelligent dance music.

This week is unique for us, as it's not a direct structural engineering resource but it's a topic that I am certain you need to understand while you plan out your career. Zach and I are talking with Ryan Sullivan, an engineer who left his design job to go after a passion in financial planning. This is a great story for all the engineers with a pocket full of "numbers" questions, and we finally have the right person to ask. So join in while we learn how we should think about this critical, and engineering adjacent, decision framework for your work life. Ryan Website can be found here: https://www.obpfinancial.com/And I also wanted to link in Connor's (Episode 77) new Python course, I'll certainly be joining in since I see this as a beneficial future set of skills for our profession, Check it out here:https://www.structuralpython.com/

​​Universities and colleges in New Brunswick have an idea of how many international study permits they may get for the upcoming school year, but the math isn't very encouraging. Jeanne Armstrong spoke to Ryan Sullivan, associate vice president of enrolment management at St. Thomas University.

Send us a Text Message.Ever thought about starting your own podcast? In this episode, I'm with Ryan Sullivan, founder of Podcast Principles. We dive into everything you need to know to start, grow and scale your podcast. You can visit his website here.----Hi, I'm your host Natalie Nadeau.Self-evolution coach for business leaders.→ I help you + your business grow in 90 days.Book a chat with me.Follow me on LinkedIn. PodMatchPodMatch Automatically Matches Ideal Podcast Guests and Hosts For Interviews Make More with Matt HeslinExplore strategies to thrive financially, build legacy, and enhance life experiences.Listen on: Apple Podcasts SpotifySupport the Show.

The federal government is capping the number of study visas it issues to international students. What will the change mean for local colleges and universities? We speak to Ryan Sullivan, vice president of enrollment at St. Thomas University in Fredericton.

Jake and Mike are joined by Ryan Sullivan of Cover 1 (@SportsRoc2) to discuss the Bills AFC East championship and their upcoming Wild Card matchup against Pittsburgh Victory Thursday - 2:00 Steelers Preview - 25:00 Biggest advantages for both teams - 40:00 Wild Card Weekend Preview - 46:00 Follow us @PayTheBillsPod Sponsored by Outlet Liquor

 I help people launch top 3% podcasts with 0 paid promotionin 5 meetings or less using a proven launch strategy to create content peopleactually want to watch.   Beyond that, I'm SullyBop; I live a second life as a rapperand DJ of 8 years performing and hosting over 300 live events.   If a mechanic can figure it out, so can you.  About Ryan Sullivan  First, thank you for reading. This is my bio, so be awarethat I'm going deep on, "me" but I don't expect our episode to be some-centric, unless you want it to.   TLDR on Sully:   - Worked as a mechanic for 4 years, sold and flipped 30+cars  - Made $80 my first 90 days of freelancing and beenindependent ever since   - Took 3.5g of mushrooms and almost died on a river, butescaped to tell the story   - Found and paid mentors along the way who are now my peers  - Launched a podcast in my parents garage that now reachesthousands  - Released 2 mixtapes, 1 album and created 100+ songs with 0experience   - Launched a podcast coaching agency and hired my bestfriends to help  The Story:   One of my first podcast guests, Brian Conklin passed away ina tragic car accident in 2021. Most of what I do today is inspired by him andmy biggest accomplishment is the fact that his family can hear him speak for 2hours because of that episode. Money, followers - none of it is important inthe end, and that's what I'm focused on.   At the age of 16, I started recording hiphop music withfriends. Since then, I've developed a brand around my stage name,"SullyBop." I've DJ'd, performed and hosted hundred of events andit's undoubtedly an interest, turned passion.   I launched a podcast on a whim in 2018 after watchingcountless hours of Gary Vee. After meeting him in 2019, I vowed to dedicate mylife to creating a business around helping people create podcasts. Since then,I've interviewed over 100 people on my show, and helped over 100 morepodcasters and future podcasters.  I have found a way to pursue my dreams at 24 years old and Icouldn't be more grateful to share some time with you on your show.  http://www.sullybop.com/  https://www.facebook.com/sullybop  https://www.instagram.com/sullybop/  https://www.linkedin.com/in/sullybop/  https://www.tiktok.com/@sullybop  https://twitter.com/TheSullyBop  https://youtu.be/syPD--FdtXI        

Deuteronomy 6:1-9 | Ryan Sullivan | November 10th, 2023

THE KELLY CARDENAS PODCAST PRESENTS RYAN SULLIVAN Thank you for rocking with the podcast. Podcast MERCH is now available ⁠⁠here⁠⁠ BESTSELLING BOOK “THE VIBE- the missing ingredient that changes everything”  Thank you to our sponsors ⁠⁠⁠THE VIBE ROOM⁠⁠⁠ Be sure to check out my new audiobook ⁠⁠⁠SUCCESS LEAVES CLUES⁠⁠⁠ (THE 7 P'S THAT CAN SHIFT YOUR REALITY) POPPINGTON'S POPCORN Code: KELLYVIBE ⁠⁠⁠⁠⁠⁠Findlay Volvo Las Vegas⁠⁠⁠ ⁠⁠⁠PRIVATE MONEY CLUB⁠⁠⁠  USE CODE - KELLY500 ⁠⁠⁠MONEY SCHOOL⁠⁠⁠ ⁠⁠⁠TABLE ONE HOSPITALITY⁠⁠⁠ ⁠⁠⁠RAVEN DRUM FOUNDATION⁠⁠⁠ ⁠⁠⁠THE MINA GROUP⁠⁠⁠ ⁠⁠⁠SECRET KNOCK⁠⁠⁠ ⁠⁠⁠Cardenas Law Group⁠⁠⁠ ⁠⁠⁠Squeeze Dried⁠⁠⁠ ⁠⁠⁠BLING SHINE SERUM⁠⁠⁠-The #1 seller of over 15 years and the only product to be endorsed by my MAMA! MORE ⁠⁠⁠KELLY⁠⁠⁠ “JOY IS THE ART OF FALLING IN LOVE WITH YOUR CURRENT CIRCUMSTANCES AND ALLOWING MAGIC TO HAPPEN!” EXECUTIVE PRODUCER MAKENA CARDENAS --- Send in a voice message: https://podcasters.spotify.com/pod/show/kelly-cardenas/message

One of the most valuable skills in today's world is the ability to improvise.  Improvisation is not just about making things up on the spot but also about adapting to changing situations, finding creative solutions, and collaborating with others. In this episode, Billy and Shaun Peterson sit down with Ryan Sullivan, CFP®, CRPC®, RCC™, Vice … Read More Read More

The conclusion of the murder of Ryan Sullivan. Find out who betrayed him and how it was all carried out.

Ryan Sullivan fell in love with a girl named Melissa he met online while he was deployed, when he got back home he met Kathy who had been pretending to be Melissa. That was the first of many twists in this case.   Part 1 of 2.  Don't want to wait a week for part 2? Join us at Patreon for part 2.  Check out the video with pictures on patreon.com/strangerdangerpodcast   

We're here to pay the bills! Ryan Sullivan of Cover 1 joins and we draft our win totals teams for the season. 1:00 – Intro 3:00 – Bills Starter's performance in Pittsburgh; expectations for Chicago 14:00 – Win Totals Draft! Follow us @PayTheBillsPod

Out Live from Dervo's Deli with a Juicey pod this week. First, Sports Lawyer and Agent Jill McBride Baxter discusses her experiences as a pro, how she goes about clients, being the spouse of college football coach, conference realignment insights between the Big12, PAC12, BIG10 and Mountain West then finishing up with some Fresno State talk. Second up is former Fresno State Baseball standout Ryan Sullivan as he discusses his college baseball experience and a different perspective on this conference realignment madness and how it will reflect other sports programs. Third, the voice of Fresno State Athletics and seasoned vet announcer Paul Loeffler talks to discuss the outlook of Fresno State Football, the competitive nature of the valley, and talks about one of his patriotic successful passions in his show Hometown Hero's which features veterans telling there story that impacted this country. Lastly, we get an electric sit down with Fresno State diehard Chris Healy. You may have seen him and his company on shark tank signing a deal with Mark Cuban… but the longhairs are changing the game for dudes with long hair. Chris has the fired up energy about how the valley and Fresno State have been a pivotal part of his success and that those roots run deep. Love to see it. Lots of juice.

Are you on social media? Do you hope and wish to grow your platform? Then this is the episode for you! Today, I interview and connect with Ryan Sullivan, a runner who works for a digital marketing agency. He first discusses his journey with running and how he became passionate about the running community and social media. Then, we hear some practical and powerful tips about how to grow your social media platform, whether it's Instagram, TikTok, Youtube, or anything in between! He offers great advice on how to stay true to who YOU are while also building a strong platform. Finally, he gives my own Instagram account (an.athletes.apron) a personal audit! We talk about my account, what I do well, and what I personally could improve on as an example for many of you to follow for your own accounts! I am confident that if you want to grow your platform, you will come away from this episode with guidance and tips. You can connect with Ryan through his Instagram (rysulli). Ryan's Instagram: https://www.instagram.com/rysulli/ My Instagram: https://www.instagram.com/an.athletes.apron/ --- Support this podcast: https://podcasters.spotify.com/pod/show/sabrina30353/support

Dr. Diwakar Davar and Dr. Jason Luke discuss advances in melanoma, including targeted therapy and the addition of LAG-3 inhibitors to checkpoint therapy, as well as promising checkpoint inhibitors in cutaneous squamous cell carcinoma and Merkel cell carcinoma in advance of the 2023 ASCO Annual Meeting.  TRANSCRIPT Dr. Diwakar Davar: Hello, and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Diwakar Davar, and I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. I'm delighted to welcome my colleague and friend, Dr. Jason Luke. Dr. Luke is an associate professor of medicine and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh's Hillman Cancer Center. He is a very, very well-renowned physician-scientist who has done fundamental work in developmental therapeutics and also in melanoma.  Today, we'll be discussing some key oral abstracts highlighting advances in immunotherapy in the cutaneous malignancy space that will be featured at the 2023 ASCO Annual Meeting.   You will find our full disclosures in the transcript of this episode and the disclosures of all guests on the ASCO Daily News Podcast are available in our transcripts at asco.org/DNpod.  Jason, thank you for coming on the podcast today. Dr. Jason Luke: Well, thanks so much for the opportunity. Dr. Diwakar Davar: So, we will go right ahead into the abstracts and the first one we thought we'd discuss is Abstract 9502, which is the RELATIVITY-047 study, specifically the 2-year results. This is the update. This has also been concurrently published at the New England Journal of Medicine Evidence online. And so in this publication and oral presentation, Hussein Tawbi, Georgina Long, and colleagues are talking about the nivo-rela data in the context of metastatic melanoma. So what is your take on this? What is your take on the data both presented and published and how would you contextualize this for the audience? Dr. Jason Luke: Right, so the RELATIVITY-047 study, as people will remember, randomized treatment-naive patients with metastatic melanoma to either receive nivolumab as standard treatment as a monotherapy or the combination of nivolumab and the anti-LAG-3 antibody relatlimab. And that study reported out a couple of years ago showing the improvement in progression-free survival as the primary endpoint. And at the time we saw that difference was approximately a 6-month absolute difference. And eventually, we saw there was an increase in the overall response rate also, again, approximately on the order of about a 10% change. What was interesting was that the overall survival initially was immature and that was an interesting follow-up point that we wanted to see. So I think what's important in seeing now this 2-year update of these data are the maintenance of the benefit for nivolumab plus relatlimab as compared to nivolumab alone across those measurements of progression-free survival and overall response rate.  Interestingly, the overall survival in the clinical trial actually did not meet the pre-specified threshold for statistical significance. That being said, when you look at the data presented in the Kaplan-Meier plots and you think about the difference, it really does appear that there's a clinically meaningful difference between these 2 groups. And the statistical cut point only missed by about .01. And so this is one of those areas where one wonders whether or not subsequent therapies may have impacted on the overall survival calculation because obviously, patients in this trial had not received ipilimumab or a PD-1 CTLA-4 combination. So the take-home message from me in this data set was that the benefit of nivolumab and relatlimab was sustained over time and there was no suggestion of any late toxicities that might make us concerned.   One advantage of this combination of nivolumab and relatlimab is the dramatically improved side effect profile relative to nivolumab and ipilimumab. So whereas immune-related adverse events that were serious, grade 3-4 is approximately 50% for nivolumab and ipilimumab, in the RELATIVITY-047 study, we see that the incidence of grade 3-4 toxicities for nivolumab and relatlimab is 17.2%, so that's less than half. So that's pretty attractive. And when we think about frontline management of patients, I think these data really support that nivolumab plus relatlimab is a reasonable consideration for some patients. And now I think the future question is really going to be, okay, well then who should get nivolumab and relatlimab versus who should still get nivolumab plus ipilimumab? Obviously, these data do not address that, and I think that that's probably the most important question for metastatic disease that's probably on the horizon. Dr. Diwakar Davar: Thank you, Jason, those are all fantastic points. It is interesting to note that as a result of the data, or really the lack thereof, the combination is actually not being launched in certain countries. So, for example, the German Health Authority, GBA, the Federal Joint Committee in Germany has decided against the acceptance of this agent because it does not accept event-free survival (EFS) as a patient-relevant endpoint. So it's interesting that we have an agent that is now going to be FDA-approved. It's already FDA-approved and available in the United States, but it will not be at least available in Germany and there may be other countries that decide favorably or unfavorably depending on how this OS data is viewed.   So pivoting to another LAG-3 inhibitor in this case fianlimab, we're going to discuss Abstract 9501. So Abstract 9501 essentially is describing a phase II trial that evaluated the LAG-3 inhibitor, fianlimab, along with the anti-PD-1 inhibitor, cemiplimab from Regeneron. The data is slightly different from what we have seen with RELATIVITY-047, the Opdualag combination. So Jason, how would you contextualize the fian-cemi combination in advanced melanoma in the context of what we've seen with RELATIVITY-047? If you could help us with that, please. Dr. Jason Luke: Yeah, absolutely. So before we dive into this specific abstract, it's, like you mentioned, probably useful to just put all of this in context. Targeting LAG-3 as an immunomodulatory approach has actually been in clinic for a decade approximately. And so the relatlimab phase 1 started quite a long time ago. And there was data for nivolumab and relatlimab in PD-1 refractory patients with melanoma that showed not a tremendously obvious level of activity. And so it was thought there that the only place they would see that activity was to go to a frontline randomized phase 2 and then phase 3 trial, as we just discussed.  In contrast to that, given all the data that had come forward about LAG-3 targeting with relatlimab, the group developing fianlimab took a different approach and rather treated a cohort of patients with treatment-naive melanoma to try to get an initial assessment right away of the activity as read out by overall response rate for this PD-1 plus LAG-3 combination, which is cemiplamab plus fianlimab.   And these authors have previously presented data about this combination from cohorts of patients who are treatment-naive who received this combination and described approximately a 64% overall response rate. And that's an impressive number in the treatment-naive setting. There's sort of a tension there to sort of say, well, wait a minute, the response rate in this single-arm study is 64%, but in RELATIVITY-047, the response rate was lower for the LAG-3 combination and I think that's not a fair comparison. We have to realize this is a much smaller group of patients that has the potential to have been somewhat biased towards a better cohort just because of where and when they were recruited to participate in this trial. All the same, I think that number does look impressive and suggest that this combination is active in the frontline.   Specific to this abstract, though, what the authors presented here was to update those previous data and then specifically also to focus on a cohort of patients who are allowed to have had previous treatment in the perioperative setting. So either neoadjuvant or adjuvant therapies. And in a subgroup of patients, they observed that even in the patients that had received adjuvant anti-PD-1 who went on to then progress later, they got actually a similar overall response rate at approximately 60% even in that group. And so I think that that seems like an exciting number as well. One would on first principles think that if patients got an adjuvant anti-PD-1, then a PD-1 LAG-3 combo could be less active. When and how the patients progressed or did not on that adjuvant therapy, however, I think makes a big difference. And given the relatively small sample size of patients that were included in this report, which is on the order of 20-ish patients who were in the previous PD-1 treated adjuvant cohort, I don't know that we can make super broad analyses trying to compare across the development programs.  What I would take from this abstract, however, is that it does appear that this other PD-1 LAG-3 combination cemiplamab plus fianlimab is also very active and certainly deserves to be investigated in similar clinical trial contexts as the nivolumab plus relatlimab combination that we previously discussed. And while it's not specifically stated here, that is happening, there is a frontline phase 3 trial for this combination of fianlimab and cemiplamab as well as adjuvant considerations, also ongoing. Dr. Diwakar Davar: So, thank you. We've seen a lot of LAG-3 data this last 2 months, the phase 2/3a RELATIVITY-020 trial has just been published in the JCO, I encourage people to read that. And so that was the evaluation of nivolumab and relatlimabin the post-PD-1 patient population that Jason alluded to, where the response rate that was observed was 12%. So we've seen a lot of interesting data, a lot of interesting survival data, and now a new potential combination with LAG-3 with fianlimab and cemiplamab from Regeneron. So it'll be a very interesting next couple of years as we see whether or not this new combination, how it shakes up against the established nivu-rela combination, again, albeit with the limitations of cross-trial comparisons and also how it performs against cemiplamab in this ongoing, as you alluded to, ongoing global phase 3 trial.  So, pivoting away from melanoma, now addressing the context of another cutaneous malignancy, a very high-risk one, Merkel cell carcinoma. So, Merkel cell carcinoma for those who are not necessarily treating a lot of this is a very rare and very aggressive cutaneous tumor. It's a neuroendocrine tumor of the skin. It's a cancer that's typically associated more than about 60% of the time with a cancer-causing virus, an oncogenic virus known as a Merkel Cell Polyomavirus.   And in this setting, checkpoint inhibitor therapy has been approved for the last couple of years, initially with a PDL-1 inhibitor, avelumab, and then more recently with a PD-1 inhibitor, pembrolizumab. And, at this point in time, there are three FDA-approved agents that are checkpoint inhibitors that are available for the treatment of this disease.   And CheckMate-358 was essentially a trial of nivolumab plus/minus ipilimumab in the setting of this Merkel cell carcinoma. So, Jason, what are your thoughts on how the addition of ipi did in this setting [in Abstract 9506]?  Dr. Jason Luke: Yeah, so I think this is a really interesting abstract because there's a slightly more context even than what you alluded to there. This study is an open-label, multi-cohort, but single-arm investigation where one cohort of patients received nivolumab alone and the other cohort received ipilimumab. It needs to be buttressed by a previous publication in The Lancet last year by the group at the Moffitt Cancer Center who also did a prospective study looking at nivolumab and ipilimumab. In that previous study that the Moffit group did, they got a response rate of 100%. All patients responded to the combination of nivolumab and ipilimumab in their study and that was quite provocative, suggesting that while anti-PD-1 alone has about a 50% response rate, adding ipi in that scenario then took it to 100. So these data were very much of interest because this could be a confirmatory data set to suggest for this rare tumor that perhaps a combination regimen should be preferred. Of course, one has to remember that adding ipilimumab to anti-PD-1 substantially enhances the toxicity profile. And these patients tend to be elderly that develop this kind of cancer, Merkel cell carcinoma. So that's a rather important caveat.   Just to get to the crux of what happened in this trial. As opposed to the previous Moffit trial, there actually did not appear to be a major increase in the benefit of adding ipilimumab, at least in this trial. Because again, in parallel cohorts, the NIVO monotherapy arm had a 60% response rate, which is roughly a little bit higher, but roughly in line with what we've seen previously. And the response rate to nivolumab plus ipilimumab was 58%. So, I mean basically the same. So, how can it be then, that we have this previous very high-profile publication that says 100% response? Now, we have a second publication that says adding ipi doesn't do anything - that's confusing, and I think it'll be really important to try to look at what were the differences between these two cohorts of patients. Did one of them have higher risk features, greater disease burden, et cetera? We don't really know that just yet, but trying to tease that out will be important.  This data also emphasized, though, the complexity around the dosing of ipilimumab. And in melanoma, we never really figured out what the best dose of ipilimumab was to give either alone or even in combination with a PD-1. And we don't really have time to get into all of it right away here, but there are multiple studies in melanoma that would suggest that giving ipi on an every 3-week dosing schedule is superior to giving it on a 6-week dosing schedule. In this study, they did use the 6-week dosing schedule. So, whether or not that could have made a difference, I guess, is unknown. But I would notice that in the previous Moffitt trial, they also used that six-week dosing schedule. This one's a head-scratcher for why did these data not confirm a previous data set? But for the time being, I think this emphasizes that PD-1 monotherapy really is the standard approach that should be considered for patients with metastatic Merkel cell carcinoma.  Dr. Diwakar Davar: That's great, Jason. And so, again, it's a very tough patient population. These are very rare patients. The Moffitt trial that Jason alluded to essentially was a trial that had in each arm, there were approximately 25 patients, of which 13, or between 11 to 13 patients were actually checkpoint inhibitor naive, wherein the dramatic 100% response rate was seen. And this is a trial where at least in this update, we've got about 25 patients in nivo monotherapy, I mean in 43 patients. And so, in a disease that is thought to be extraordinarily sensitive to checkpoint inhibitor immunotherapy because of the role of the virus and the high TMB that it's associated with, it is very interesting that the addition of an additional checkpoint inhibitor did not appear to improve outcomes. But as you alluded to multiple reasons, but we don't know how it's going to shake out. Next, Abstract 9507 and this is a very interesting trial known as the MATISSE trial. So, in the context of cutaneous squamous cell carcinoma, cutaneous squamous cell carcinoma is a relatively not uncommon cancer, primarily seen in older cancer patients, particularly a little bit more common in men. And in this setting, we've got checkpoint inhibitor therapy that is FDA-approved, at least two of which are FDA-approved right now, pembrolizumab and cemiplamab both were approved in the advanced cancer setting. And we do know that because of the extraordinarily high tumor mutation burden associated with cutaneous squamous cell carcinoma, checkpoint inhibitor therapy has got a very dramatic effect. Response rates are between 35% to 42% with pembrolizumab and 40% to 50% with cemiplamab, depending on whether or not one looks at the relapsed metastatic or the locally advanced patient populations.  And interestingly, much like we've seen with melanoma, we have migrated the use of this therapy early in the lines of patients, particularly in the setting of perioperative therapy. So, Jason, how would you contextualize the results of the MATISSE trial in relation to the existing and known data from several of our colleagues regarding the role of what checkpoint inhibitor therapy is doing in terms of organ preservation?  Dr. Jason Luke: Yeah, and I think this is an area of tremendous excitement. And as you were alluding to, the activity of anti-PD-1 really was transformative in this disease, which really can be a disfiguring and locally destructive disease. And with that activity for unresectable disease, last year, near the end of the year, there was a first report of a large neo-adjuvant clinical trial in cutaneous squamous which showed really outstanding results in terms of improving surgery and pathologic complete response using anti-PD-1 in that setting. And for this trial, this was a trial done in Europe; they took a similar tact of trying to think about giving anti-PD-1 or anti-PD-1 with anti-CTLA-4 with ipilimumab in that neoadjuvant period to see whether or not they could reduce the use of extensive surgery and/or radiation therapy.  The short version is they were able to do that. And so they described 40% of patients with single-agent anti-PD-1 and 53% of patients who received a combination having major pathologic response to treatment. And this was so much so that 10 of the patients who had pathologic responses actually withdrew their consent to go on to have surgery because they decided that they had had such a good effect of the immunotherapy, they weren't willing to put themselves through what was going to be a very difficult surgery. And I think that speaks to the upside potential of these checkpoint immunotherapy approaches in certain settings, specifically here in cutaneous squamous cell carcinoma. Moreover, they describe clinical response in neoadjuvant setting as 50% for PD-1 monotherapy and 61% for the combination and I really think that this is really ready for prime time.  With the study published in the New England Journal last year and these data now, I really think the field needs to start moving towards the use of perioperative anti-PD-1 with or without ipilimumab as a standard approach. And I think it's the case that even the NCCN and ASCO and various guideline societies are going to start acknowledging that this ought to be considered for most patients who are facing difficult surgical operations for continuous squamous cell carcinoma. Dr. Diwakar Davar: So, Jason, you bring up a fascinating point, which is the appearance of this in guidelines. So this is undoubtedly extraordinarily good data. It's confirmatory, the pathologic response rates in many ways paradoxically low. You'd expect something about 50% or so. But the reason it's low is because 10% of patients who actually benefited didn't undergo surgery. So really the degree of benefit is tremendous. It's about 50% to 60%. So the fascinating thing in the setting that we'd have is if one is going to try to get the drug FDA-approved, what we now have is the conventional setting in which one needs a definitive endpoint. And at least we know that pathological response rate is not a definitive endpoint in the context of melanoma or, for that matter, cutaneous squamous cell carcinoma. The only setting in which it is a regulatory endpoint is a non-small cell lung cancer or triple-negative breast cancer. But recently there's been some very exciting data from another PD-1 inhibitor called dostarlimab in a trial done by your former colleague Dr. Luis Diaz when he demonstrated a dramatic result of dostarlimab in the context of perioperative rectal cancer where it is micro-satellite high wherein the standard of care is typically very disfiguring abdominal perineal resection.    So in the context of some of our listeners who might be thinking a little bit about how this pertains to regulatory approval, what are your thoughts about the paradigm of avoiding highly disfiguring surgery relating to what was seen in the rectal cancer discussion to what we're now seeing with perioperative therapy in the context of cutaneous squamous cell carcinoma?  Dr. Jason Luke: I think it's a very important question. And the easy out for diseases that have a pattern of progression that is metastasis is to use event-free survival which can include both the pre-surgical and the post-surgical period in terms of looking for whether or not the cancer comes back. And that works for diseases potentially like lung cancer, like you said, maybe melanoma. In cutaneous squamous cell carcinoma, however, that's not probably going to work because this tends to be a locally invasive and less of a metastatic disease. So here then, we really need to have sort of organization across patient advocacy, dermatology, medical oncology to come up with what the most appropriate considerations are going to be for evaluating that long-term benefit because I think we need a tangible result that we can show the FDA. Everyone is really impressed by these results, and I think that next step is to craft this into a way that we have a measurable output that we can then go to them with and say bless this so that all of our patients can get this kind of treatment. Dr. Diwakar Davar: Really great discussion, Jason. And I think this is going to be an area of particular interest going forward, given both the number of trials that have been conducted in this space and also the role of the very interesting regulatory paradigm that has now been set initially at least with the rectal cancer that is microsatellite high and now potentially we will see with cutaneous squamous cell carcinoma.   And so the final abstract that we have selected for you is Abstract 9511. And this is a trial that was conducted by a mutual colleague, Dr. Ryan Sullivan, and his colleagues. And it's essentially a trial of looking at targeted therapy with or without navitoclax in BRAF mutant melanoma patients. And part of the reason to highlight this, it's very interesting preclinical data supporting the addition of navitoclax, b but also a great example of an early trial that came through the CTEP portfolio. And so Jason, can you tell us about why this is exciting and how we might contextualize the addition of navitoclax to the targeted therapy backbone?   Dr. Jason Luke: Sure. So listeners will be quite aware of targeting mutant BRAF as a therapeutic strategy across oncology that was really initially pioneered in melanoma with the development of vemurafenib as the first selective BRAF inhibitor. But the field, of course, moved eventually to BRAF and MEK combinations across essentially all settings. We know that dabrafenib and trametinib are now approved pan-cancer for anywhere we find a BRAF V600e mutation. In the context of melanoma, looking at mechanisms of resistance, we observed that they were quite heterogeneous with reactivation of elements of the mitogen-activated protein kinase pathway, the MAPK pathway. But also there were metabolic changes in the cancer cells themselves which could drive resistance and were downstream of some of those reactivation signaling points. So one of those is the induction of anti-apoptotic machinery in the cell. So activation of BCL-2 or Bcl-xL to try to save those melanoma cells when they were under stress by blockade with BRAF and MEK inhibitors. And that observation was made now about a decade ago or more. And that raised the possibility that repurposing a drug that was being used actually in the chemo malignancy space might be useful in augmenting targeted therapy. And that's where we come in with the navitoclax as a BH3-mimetic that can actually knock down those antiapoptotic proteins, BCL-2 Bcl-xL. And so that was the context for this initially phase I clinical trial of combining navitoclax with the dabrafenib and trametinib.  And those data supported the safety of doing that and moved to this study, which was a randomized phase 2 study of that triplet regiment versus the dabrafenib and trametinib alone. And so this study started quite a long time ago, before the sort of initiation or widespread use of anti-PD-1 antibodies. And so it had to kind of undergo some various iterations throughout its course but eventually has now read out. And it had two primary endpoints, with one being focused on improving the complete response rate for targeted therapy because that's been associated with long-term outcomes as well as to look at the maximum tumor shrinkage of patients within this trial and of course to look at other endpoints like response rate, progression-free survival, et cetera.  About half the patients who participated in the trial had prior immune checkpoint blockade and they were actually distributed evenly across the two arms. So we think that probably won't impact on the outcomes. And what was observed in the clinical trial was that in fact, the triplet did improve the complete response rate for targeted therapy. So navitoclax plus dabrafenib and trametinib had a complete response rate of 20% versus dabrafenib and trametinib alone being at 15%. Both of them had an overall response rate in the 80% range, with slightly higher for the triplet at 84% versus 80% for the double-edged standard therapy. There was also a suggestion that there may be a disproportionate benefit for the triplet actually in patients with smaller baseline tumors. And we know that the efficacy of targeted therapy is more pronounced in the lower-volume disease state.   And so overall, when we look at this without really adding much toxicity, I think this is an intriguing place to look at further drug development. BRAF and MEK inhibition has been a backbone therapy in Melanoma for a long time, but we really haven't been able to move past it or augment it in any real way because of the heterogeneity of treatment resistance. And here, by going after metabolic changes, we perhaps might have the opportunity to enhance our targeted therapy somewhat further. And so we'll look forward to further results investigating this regimen in subsequent clinical trials. Dr. Diwakar Davar: Fantastic discussion, Jason. So these are all great insights. As you've heard, we've now discussed a couple of key abstracts covering major topics that will be presented, major themes of the malignancy space at ASCO 2023, including the addition of a lactate inhibitor to checkpoint in both a randomized large phase 3 trial and a smaller phase 2 trial, the context of targeted-therapy in melanoma making another forerun in the post-3c setting. And two very interesting studies I have looked at, checkpoint inhibitor therapy in the context of cutaneous squamous cell carcinoma and Merkel cell carcinoma, addressing themes that are of huge importance going forward, including the role of perioperative therapy in squam and the addition of a CTLA-4 inhibitor in Merkel. These oral abstracts are all going to be presented at the 2023 ASCO Annual Meeting. We look forward to seeing you there.  So, thank you Jason for taking the time to join us and for highlighting these important advances in immunotherapy. And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcast. Thank you for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers: Dr. Diwakar Davar @diwakardavar Dr. Jason Luke @jasonlukemd   Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures:  Dr. Diwakar Davar:  Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences Consulting or Advisory Role: Instil Bio, Vedanta Biosciences Consulting or Advisory Role (Immediate family member): Shionogi Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences Research Funding (Inst.): Zucero Therapeutics Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy  Dr. Jason Luke:  Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical , Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof) Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Chris was asked to be on Bopcast, hosted by Ryan Sullivan, to chat through Chris' journey into entrepreneurship. He offers encouragement and perspective to anyone carving their own path. They discuss developing a personal brand, Chris' aspirations, learning theory, routines, and the importance of following through on promises to yourself. If you have questions for Chris, join the Revenue Vitals Live conversation on zoom by registering here, or submit them ahead of the call here! Also make sure to check out The Vault, where you can find full depth insights and IP beyond the high level live event. Thanks to our friends at Hatch for producing this episode. Get unlimited podcast editing at usehatch.fm.

Kevin welcomes Ryan Sullivan,Ryan Sullivan, Advisor for Warehowz, on the show to talk about the next big thing in FreightTech. Is it AI? Is it automation? Is it collaborating with rivals? We explore all the possibilities this hot market has in store for the logistics industry. #sales #PutThatCoffeeDown #marketing #freightsales #freightwaves #sonarAt UniGroup Logistics, getting you from point A to Point B is just the beginning. We're the problem-solvers that drive, that move, that hustle day in and day out. So your company can reach, lead, thrive and drive the future.Follow the Put That Coffee Down PodcastOther FreightWaves Shows

Kevin welcomes Ryan Sullivan,Ryan Sullivan, Advisor for Warehowz, on the show to talk about the next big thing in FreightTech. Is it AI? Is it automation? Is it collaborating with rivals? We explore all the possibilities this hot market has in store for the logistics industry. #sales #PutThatCoffeeDown #marketing #freightsales #freightwaves #sonarFollow the Put That Coffee Down PodcastOther FreightWaves Shows

➡️ Like The Podcast? Leave A Rating: https://ratethispodcast.com/successstory ➡️ About The Guest⁣ Ryan Sullivan is the brains behind Podcast Principles. Starting as an audio engineer, music artist, and podcaster, he transformed his passions from a side hustle into a career. Ryan has launched 15+ podcasts and interviewed over 200 people across 5 shows working with celebrities, athletes, business moguls and more. ➡️ Show Links https://www.linkedin.com/in/sullybop/ ➡️ Watch the Episodes On Youtube https://www.youtube.com/c/scottdclary Learn more about your ad choices. Visit podcastchoices.com/adchoices

Air Raid Hour | Tilt and Ryan Sullivan lead a therapy session after the Bills fell to the Jets 20-17 on Sunday. What went wrong? How can the Bills fix it?

Air Raid Hour | Tilt and Ryan Sullivan lead a therapy session after the Bills fell to the Jets 20-17 on Sunday. What went wrong? How can the Bills fix it?